Cost-Effectiveness Analysis for Policy
Also known as: Policy Cost-Effectiveness Analysis, CEA for Policy, Cost-Utility Analysis in Policy
Cost-effectiveness analysis (CEA) is an economic evaluation that compares competing policies or programs by their cost relative to a single, common measure of effect — lives saved, cases averted, years of education gained, or quality-adjusted life years (QALYs). Rather than valuing outcomes in money, CEA expresses results as an incremental cost-effectiveness ratio (ICER): the extra cost of one option per extra unit of outcome it delivers compared with the next-best alternative. Codified in standard references such as Drummond and colleagues' Methods for the Economic Evaluation of Health Care Programmes and the US Panel's Cost-Effectiveness in Health and Medicine, CEA is the dominant appraisal tool for health and increasingly for other public programs with a shared outcome metric.
Key highlights
- Avoids the controversial step of placing a monetary value on outcomes such as lives or health, sidestepping a major objection to cost-benefit analysis.
- Produces an intuitive, comparable metric — cost per unit of effect — that supports prioritisation across competing programs under a fixed budget.
- Well-established methods and reporting standards (e.g., CHEERS) give it transparency and credibility in health and beyond.
- Probabilistic sensitivity analysis provides a rigorous account of decision uncertainty rather than a single deterministic answer.
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
Use cost-effectiveness analysis when comparing programs that share a single, well-defined outcome and decision-makers want the most effect per unit of cost without monetising the outcome itself. It is the standard tool in health technology assessment and is increasingly applied to education, social and environmental programs with a common effect measure. It is most appropriate when the outcome of interest is one-dimensional and comparable across options. It is unsuitable when programs produce fundamentally different kinds of benefits that cannot be reduced to one metric (where cost-benefit or multi-criteria analysis is needed), when the absolute worth of the outcome must be established rather than relative value, or when the budget and threshold are entirely undefined.
Strengths & limitations
- Avoids the controversial step of placing a monetary value on outcomes such as lives or health, sidestepping a major objection to cost-benefit analysis.
- Produces an intuitive, comparable metric — cost per unit of effect — that supports prioritisation across competing programs under a fixed budget.
- Well-established methods and reporting standards (e.g., CHEERS) give it transparency and credibility in health and beyond.
- Probabilistic sensitivity analysis provides a rigorous account of decision uncertainty rather than a single deterministic answer.
- Can only compare programs that share the same outcome measure; it cannot weigh heterogeneous benefits against one another.
- Reduces value to a single dimension, ignoring other consequences (equity, broader welfare) unless captured separately.
- Requires a willingness-to-pay threshold to reach a decision, and that threshold is often implicit, contested or absent.
- Results are sensitive to the chosen perspective, time horizon, discount rate and costing boundaries, which can be set inconsistently.
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
What is the difference between cost-effectiveness analysis and cost-benefit analysis?
Cost-benefit analysis converts all outcomes into money and asks whether monetised benefits exceed costs, producing a net benefit or benefit-cost ratio comparable across very different policies. Cost-effectiveness analysis leaves the outcome in natural units (lives, QALYs, learning gains) and reports cost per unit of that outcome, so it avoids monetising the benefit but can only compare programs sharing the same outcome. CEA is preferred when valuing the outcome in money is contentious; CBA is preferred when benefits are heterogeneous and must be made commensurable.
What is an ICER and how is it interpreted?
The incremental cost-effectiveness ratio is the additional cost of one option divided by its additional effect relative to the next-best comparator — for example, extra dollars per extra QALY. It is interpreted by comparison with a willingness-to-pay threshold: if the ICER is below the threshold, the extra effect is judged worth the extra cost. An option that is both cheaper and more effective 'dominates' and needs no ratio; the ICER matters when an option costs more but also achieves more.
What is a cost-effectiveness acceptability curve?
It is the main output of probabilistic sensitivity analysis. After assigning probability distributions to uncertain cost and effect inputs and simulating many times, the curve plots, for each possible willingness-to-pay threshold, the probability that a given option is the most cost-effective choice. It communicates decision uncertainty directly: instead of a single ICER, it tells decision-makers how confident they can be that an option is good value across the plausible range of thresholds.
Sources
- 1.Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford: Oxford University Press.ISBN 9780199665877
- 2.Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.) (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.ISBN 9780195108248
You have read it. What now?
Cite this page
ScholarGate. (2026, June 22). Cost-Effectiveness Analysis for Policy. ScholarGate. https://scholargate.app/public-policy/cost-effectiveness-analysis-policy